MA

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 4, 2021
ID, Heart failure with preserved ejection fraction, NFE2L2, Webcast, Review, Lists of diseases, Thalassemia, Therapy, Sickle cell disease, Investor, Nasdaq, Patient, GLOBE, PDE9, Pharmaceutical industry

ET to discuss its financial results for the quarter ended September 30, 2021 and review recent business highlights.

Key Points: 
  • ET to discuss its financial results for the quarter ended September 30, 2021 and review recent business highlights.
  • A live webcast will be available under Events and Presentations in the Investors section of the company's website .
  • The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 1235955.
  • A replay of the webcast will be archived on the Imara website following the presentation.

T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

Retrieved on: 
Thursday, November 4, 2021
Health, University, Adoption, Distinguishing, Business, Industry, BioSystems, Contract, Private Securities Litigation Reform Act, Datascope Analytics, Leadership, U.S. Securities and Exchange Commission, NASDAQ, CEO, Chief commercial officer, Failure, Master, Christopher Newport University, GLOBE, University of Phoenix, Political science, Johnson & Johnson, SEC, College, Marketing, Patient, FDA, Management, Medical imaging

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021.

Key Points: 
  • LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021.
  • As Chief Commercial Officer, Mr. Giffin will join the Companys executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions.
  • We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer, said John Sperzel, Chairman and CEO at T2 Biosystems.
  • Mr. Giffin brings a wealth of industry experience and commercial leadership to T2 Biosystems, having served as Chief Executive Officer for two early stage medical technology companies, as Chief Commercial Officer at Accriva Diagnostics (formerly ITC Medical), and in several sales and marketing leadership roles at Datascope, Covidien, Boston Scientific, and Johnson & Johnson.

Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, November 4, 2021
Securities Exchange Act of 1934, PK, Lists of diseases, Safety, Cancer, Radioimmunotherapy, Morphic, Private Securities Litigation Reform Act, European, Neoplasm, Clinical trial, Ulcerative colitis, Mint, Time-invariant system, BID, Security (finance), Income, Investment, ECCO, COVID-19, Securities Act of 1933, IV, Forward-looking statement, Inflammatory bowel disease, AbbVie, Biotechnology, Company, U.S. Securities and Exchange Commission, Research, GLOBE, Therapy, Pharmacodynamics, Maritime Transportation Security Act of 2002, Fibrosis, Conditional sentence, Biology, Autoimmunity, Patient, Pharmaceutical industry, Management

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter of 2021.

Key Points: 
  • MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program in ulcerative colitis expected to begin 1Q22
    Announced appointment of Nisha Nanda, Ph.D., to Morphic Board of Directors
    WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter of 2021.
  • Developing MORF-057 with our MInT platform has generated an array of learnings that feed into our earlier proprietary pipeline, driving advances in Morphics programs in immuno-oncology and other indications.
  • Net loss for the quarter ended September30, 2021 was $25.0 million or $0.69 per share, basic and diluted compared to net income of $5.4 million or $0.17 per share, diluted for the same quarter last year
    Revenue was $3.1 million for the quarter ended September30, 2021, compared to $25.8 million for the same quarter last year.
  • Morphic believes its cash, cash equivalents and marketable securities as of September30, 2021, will be sufficient to fund operating expenses and capital expenditure requirements until the end of 2024.

Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress

Retrieved on: 
Thursday, November 4, 2021
SITC, Neurology, Private Securities Litigation Reform Act, Exosome, Center, Security (finance), NASDAQ, Center of excellence, Infection, COVID, Growth, Society, Goal, Research, CTCL, Hepatocellular carcinoma, Partnership, File, Acquisition, U.S. Securities and Exchange Commission, GLOBE, Neuro-oncology, Immunotherapy, Biology, Patient, Cancer, Total, IND, Medical device, Fine chemical, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported third quarter 2021 financial results and recent operational progress.

Key Points: 
  • Initial data readout from exoSTING clinical trial expected in Q4 2021; initial data from exoIL-12 trial in CTCL patients now anticipated in H1 2022
    CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported third quarter 2021 financial results and recent operational progress.
  • We made steady progress in the third quarter toward our goals for Codiaks pipeline, said Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak.
  • Our recently announced strategic collaboration with Lonza affirms that we are at the forefront of a promising new therapeutic modality.
  • General and administrative expenses were $7.2 million for the quarter ended September 30, 2021, compared to $5.3 million for the same period in 2020.

Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 4, 2021
Twitter, Nasdaq, Therapy, Patient, GLOBE, Medical device, Medical imaging, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 financial results after the close of market on Wednesday, November 10, 2021.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 financial results after the close of market on Wednesday, November 10, 2021.
  • The company will not be conducting a teleconference in conjunction with its financial results press release.
  • Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies.
  • Relay Therapeutics initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

Virgin Pulse Adds 7 Partners to Homebase for Health®, Expanding Global Options for Addressing Top Corporate Health and Wellbeing Concerns

Retrieved on: 
Thursday, November 4, 2021
Population, Happiness, National, Martial arts, Exercise, Sports medicine, THE, Digital, Data science, Solution, Therapy, American College of Sports Medicine, Gold, Hypertension, Privacy, SWORD, Work, Mental health, GLOBE, Time, Patient, FDA, Sleep, LES, Ecosystem, Les Mills, Acnalbasac Noom, Fast Company, Organization, Degenerative disease, John Lewis Partnership, Goal, Pivot, Program, AI, Gaps, Twitter, Conditional sentence, Virgin Group, Workplace, Yoga, Centers for Disease Control and Prevention, Digital health, American College, University, Risk, Virgin Media, Pulse, LinkedIn, Friction, Center, School, Diabetes, Nasdaq, VP, Standard Chartered, Recycling, Risk management, Medical device, Medicine

PROVIDENCE, R.I., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of tech-enabled solutions focused on improving the health and wellbeing of its members, today announced the addition of seven new partners, including six global partners, as part of the company’s Winter 2021 product launch. Virgin Pulse’s partner ecosystem streamlines access to more than 50 point solutions, making it easy for companies to connect members with a broad range of specialized health and wellbeing programs. Employers and health plans can also curate a suite of pre-vetted, pre-integrated partner solutions and launch within 30 days through the one-contract VP+ partner bundle.

Key Points: 
  • Today, human resources and benefits leaders have more options than ever for managing population health conditions virtually and improving overall employee wellbeing.
  • To address the markets need for condition management tools, Virgin Pulse is expanding its digital formulary of mental health, diabetes, heart disease and other clinical condition point solutions.
  • Virgin Pulses partner ecosystem helps companies close gaps in care across more than 20 health and wellbeing categories while addressing the most common and costly health concerns.
  • To optimize program utilization and user experience, all partner solutions are seamlessly integrated and accessible through Virgin Pulses Homebase for Health experience.

SEER INVESTIGATION: Block & Leviton Is Investigating Seer Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Retrieved on: 
Thursday, November 4, 2021
NASDAQ, Partnership, News, Company, GLOBE, Bears' Cave, Bear's Cave (Erpfingen), Heating, ventilation, and air conditioning

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations.

Key Points: 
  • BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations.
  • Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those losses.
  • Anyone who purchased Seer Inc. stock and has lost money may be eligible, whether or not they have sold their investment.
  • Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

For Fourth Consecutive Year, CarePlus Health Plans Attains Medicare’s Highest 5 out of 5-Star Rating for 2022

Retrieved on: 
Thursday, November 4, 2021
Professional Services, Managed Care, Other Health, Health, Women, Optical, Men, Hispanic, Insurance, Consumer, Dental, People, TTY, Humana, Health Star Rating System, CMS, Medicare, Colorectal cancer, Health, Welfare, Star, ICD-10-CM, Centers for Medicare & Medicaid Services, Dentist, Partnership, MA, Medicare Advantage, HMO, Center, Atlantic Coast, NYSE, AEP, Social services, Physician, Diabetes, Pharmacist, Ageing, Health insurance, Restaurant

Based on her positive experience, CarePlus member Maria Sanchez would rate CarePlus even higher than 5 stars.

Key Points: 
  • Based on her positive experience, CarePlus member Maria Sanchez would rate CarePlus even higher than 5 stars.
  • A plan may receive a rating between one and five stars, with five stars representing the highest rating.
  • CMS uses information from member-satisfaction surveys, health plans, and health care providers to assign overall Star Ratings to plans.
  • CarePlus Health Plans, Inc. is dedicated to improving the lives of Medicare beneficiaries in Florida.

Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
RNA transfection, Sickle cell disease, Sickle, Biotechnology, Technology, Atomic mass, Gene editing, HSPC, Security (finance), Hemoglobinopathy, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, HBS, ASH, Abstract (summary), Transfection, B cell, Annual report, Patent, CD34, Delivery, COVID-19, LNP, Liver, Nasdaq, Tissue, Therapy, LNP (newspaper), GLOBE, SCD, Mouse, Scientific programming language, Society, Polymerization, DNA, Medical imaging, Vaccine

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that preclinical data highlighting the company’s Makassar base editing approach for the potential treatment of sickle cell disease (SCD) and its proprietary lipid nanoparticle (LNP) screening capabilities will be presented during two poster sessions at the 63rd American Society of Hematology (ASH) Annual Meeting. In addition, Beam will present an overview on the application of base editing for the treatment of beta-hemoglobinopathies and other genetic blood disorders during a Scientific Program session titled, “Gene Editing 2.0: Advances in Gene Editing to Treat Genetic Blood Disorders.” The ASH Annual Meeting is being held December 11-14, 2021, virtually and in Atlanta.

Key Points: 
  • The ASH Annual Meeting is being held December 11-14, 2021, virtually and in Atlanta.
  • In preclinical studies, Beam sought to further characterize Makassar hemoglobin, evaluating its size, molecular weight, oligomerization and polymerization potential, oxygen binding properties, as well as solving its crystal structure.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.

TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Thursday, November 4, 2021
Safety, Exposition, 2021 Essex County Council election, Cancer, Myeloid leukemia, Leukemia, MDS, Abstract (summary), TargetScan, Immunotherapy, Histocompatibility, CD8, Kinetics, Patient, Society, GMP, ALL, ASH, Risk, HLA, Blood, TCR, Acute lymphoblastic leukemia, Microdeletion syndrome, Company, Fordham Road station (IND Concourse Line), Acute myeloid leukemia, RIC, Program, Nasdaq, Proteome, Therapy, HCT, AML, GLOBE, SITC, Antigen, Vaccine, Medical device

TScan is developing these products to prevent relapse following hematopoietic cell transplant (HCT) in myeloid leukemia.

Key Points: 
  • TScan is developing these products to prevent relapse following hematopoietic cell transplant (HCT) in myeloid leukemia.
  • The Company plans to file investigational new drug applications (INDs) for both programs before the end of 2021.
  • By developing TSC-100 and TSC-101, TScan aims to recreate this natural graft versus leukemia response in order to prevent relapse in patients undergoing HCT.
  • The discovery of TCR-100 was presented at the 2020 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and can be accessed here .